The process has to begin with investors who are unusually perceptive, unconventional, iconoclastic or early.

Our Offer

Investor Portal

Reasons to Invest

Important and unmet medical need

  • Celiac Disease and Non-Celiac Gluten Sensitivity are high unmet medical needs.
  • No effective medical curatives exist to date.

Untapped markets

  • The market for pharmacological solutions to celiac disease and gluten sensitivity represents a multi-billion-dollar opportunity.
  • The awareness and diagnoses for both conditions is increasing rapidly, providing a huge opportunity for growth.

High probability of success and mitigated development risk

  • Experienced management team and major milestones already achieved
  • Validated in vitro proof of concept
  • 2-way commercialisation strategy (dietary supplement and drug)
  • Imminent market entry for dietary supplement via New Dietary Ingredient Notification (NDIN) in the USA
  • Strong IP position with patents granted in all major pharma markets
  • Lean, effective infrastructure through collaboration with leading third party research, development and pharmaceutical companies

Attractive exit opportunities

  • Ongoing M&A discussions
  • Trade sale after achievement of human proof of concept for AMY02
  • Out-licensing of AMY01 as dietary supplement


Global Prevalence

1% – 1.5%

Celiac Disease

Up to 6%

Non-Celiac Gluten Sensitivity

Growth Drivers